Amgen Inc vs. Candel Therapeutics, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| AMGN | CADL | |
|---|---|---|
| Market Cap | $237.52 billion | $1.00 billion |
| Revenue (TTM) | $38.09 billion | — |
| Net Income (TTM) | $8.74 billion | $-88,531,000 |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | CADL | |
|---|---|---|
| P/E Ratio | 27.29 | — |
| Price / Book | 20.32 | 7.97 |
| Price / Sales | 6.23 | — |
CADL leads on 1 of 1 valuation factors.
Profitability
| AMGN | CADL | |
|---|---|---|
| Net Margin | 22.95% | — |
| Return on Equity | 74.80% | -70.19% |
AMGN leads on 1 of 1 profitability factors.
Dividend
| AMGN | CADL | |
|---|---|---|
| Dividend Yield | 2.29% | — |
| Payout Ratio | 62.61 | — |
AMGN and CADL split the dividend factors evenly.
Risk & Sentiment
| AMGN | CADL | |
|---|---|---|
| Short Interest | 1.66% | 0.04% |
CADL leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, CADL overview, CADL financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.